First human test of new lung scarring drug shows early safety profile
Disease control
Completed
This early-stage study tested a new drug called PMG1015 in 29 people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. The main goal was to check the drug's safety, side effects, and how it moves through the body at different doses. Researchers compared t…
Phase: PHASE1 • Sponsor: Pulmongene Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC